Overview

Immunotherapy Drugs Market is estimated to value over USD 270 billion by 2027 end with a CAGR of over 10% during the forecast period 2020 to 2027.

The increasing occurrences of targeted diseases, rising insistence for biosimilars and monoclinal antibodies, rising acceptance of immunotherapy drugs over traditional drugs are some of the key factors responsible for the immunotherapy drugs market growth. Conversely, side-effects of these drugs, issues related to the timeline and complexities in manufacturing and a high rate of attrition in the product development cycle shall impede the proliferation of the market.

Major players included in the Immunotherapy Drugs Market:
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Merck & Co
• Novartis International AG
• Johnson & Johnson
• Sanofi
• GlaxoSmithKline Plc
• Amgen Inc.
• Abbvie Inc.
• Boehringer Ingelheim
• AstraZeneca
• Immatics Biotechnologies
• Biontech SE
• Genmab
• Gilead Sciences
• NBE Therapeutics
• Teva Pharmaceuticals
• Bayer
• Bristol-Myers Squibb
• Eli Lilly And Company
• Incyte Corporation                                                                                                                                                                                                                (Note: The list of the major players will be updated with the latest market scenario and trends)

Immunotherapy Drugs Market Segmentation:

By Type
• Checkpoint Inhibitors
• Adult Vaccines
• Interleukins
• Monoclonal Antibodies
• Interferons
• Alpha And Beta
• Others

By Therapy Area
• Cancer
• Infectious Diseases
• Autoimmune & Inflammatory Diseases

By End User
• Clinics
• Hospitals
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The market is categorised into type, therapy area, end user and region. The type segment is fragmented into check point inhibitors, monoclonal antibodies, interleukins and interferons. The monoclonal antibodies segment held the largest immunotherapy drugs market share owing to fewer side effects and high specificity, rising emphasis on personalised medicines, increased prevalence of targeted diseases and growing initiatives by key market players. The therapy area segment is classified into cancer, infectious diseases and autoimmune & inflammatory diseases. Cancer segment led the market in 2019 and this can be credited to rising incidence of cancer, favourable reimbursement scenarios for oncology. The end user segment is diversified into clinics, hospitals and other end users. The hospital segment is predicted to dominate the market owing to the increased hospital expenditure for immunotherapies.

Regional Analysis:

The North America region is anticipated to dominate the market owing to rising incidences of autoimmune diseases and cancer, rising insistence for safe therapies, growing FDA approvals and favourable reimbursement scenarios.

Competitive Landscape:                            

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Immunotherapy Drugs Market By Type, By Therapy Area, By End-User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1. Objectives of the Study 
           1.2. Market Definition 
           1.3. Market Scope 
                   1.3.1. Years Considered for the Study
                   1.3.2. Market Covered
           1.4. Currency 
           1.5. Limitations 
           1.6. Stakeholders 
 2.  Research Methodology 
           2.1. Research Data 
                   2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                   2.1.2. Primary Data
                            2.1.2.1. Key Data from Primary Sources
           2.2. Market Size Estimation 
           2.3. Market Breakdown and Data Triangulation 
           2.4. Assumptions for the Study  
3. Executive Summary
           3.1. Market Outlook
           3.2. Segment Outlook
           3.3. Competitive Insights
4. Global Immunotherapy Drugs Market Variables, Trends & Scope
           4.1. Market Lineage Outlook
           4.2. Penetration and Growth Prospect Mapping
           4.3. Industry Value Chain Analysis
           4.4. Cost Analysis Breakdown
           4.5. Technology Overview
           4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Immunotherapy Drugs Market Overview
           5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                             5.1.1.1. Increasing focus of Immunotherapy Drugs Companies on Brand Protection
                             5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                             5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                             5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Immunotherapy Drugs Market Analysis Tools
           6.1. Industry Analysis - Porter’s
                   6.1.1. Supplier Power
                   6.1.2. Buyer Power
                   6.1.3. Substitution Threat
                   6.1.4. Threat from New Entrants
                   6.1.5. Competitive Rivalry
           6.2. Pestel Analysis
                   6.2.1. Political Landscape
                   6.2.2. Environmental Landscape
                   6.2.3. Social Landscape
                   6.2.4. Technology Landscape
                   6.2.5. Legal Landscape
           6.3. Major Deals And Strategic Alliances Analysis
                   6.3.1. Joint Ventures
                   6.3.2. Mergers and Acquisitions
                   6.3.3. Licensing and Partnership
                   6.3.4. Technology Collaborations
                   6.3.5. Strategic Divestments
           6.4. Market Entry Strategies
           6.5. Case Studies
7. Global Immunotherapy Drugs Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
           7.1. Checkpoint Inhibitors
           7.2. Adult Vaccines
           7.3. Interleukins
           7.4. Monoclonal Antibodies
           7.5. Interferons
           7.6. Alpha And Beta
           7.7. Others
8. Global Immunotherapy Drugs Market, By Therapy Area Historical Analysis and Forecast 2020-2027 (USD Million)
           8.1. Cancer
           8.2. Infectious Diseases
           8.3. Autoimmune & Inflammatory Diseases
9. Global Immunotherapy Drugs Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
           9.1. Hospital
           9.2. Clinics
           9.3. Others
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     10.2.1. U.S.A
                     10.2.2. Canada
                     10.2.3. Mexico
           10.3. Market Size (USD Million) Forecast for North America 2020-2027 
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     11.3.1. Brazil
                     11.3.2. Venezuela
                     11.3.3. Argentina
                     11.3.4. Rest of Latin America
           11.4. Market Size (USD Million) Forecast for Latin America 2020-2027  
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     12.2.1. Germany
                     12.2.2. U.K
                     12.2.3. France
                     12.2.4. Italy
                     12.2.5. Spain
                     12.2.6. Russia
                     12.2.7. Poland
                     12.2.8. Switzerland
                     12.2.9. Rest of Western Europe
           12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           13.1. Introduction
           13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     13.2.1. Japan
                     13.2.2. China
                     13.2.3. Singapore
                     13.2.4. India
                     13.2.5. Australia and New Zealand
                     13.2.6. ASEAN
                     13.2.7. South Korea
                     13.2.8. Taiwan
                     13.2.9. Rest of Asia Pacific
           13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           14.1. Introduction
           14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     14.2.1. Saudi Arabia
                     14.2.2. UAE
                     14.2.3. South Africa
                     14.2.4. Egypt
           14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
           15.1. F. Hoffmann-La Roche Ltd.
                     15.1.1. Company Overview
                     15.1.2. Product Portfolio
                     15.1.3. SWOT Analysis
                     15.1.4. Financial Overview
                     15.1.5. Strategic Overview
           15.2. Pfizer Inc.
                     15.2.1. Company Overview
                     15.2.2. Product Portfolio
                     15.2.3. SWOT Analysis
                     15.2.4. Financial Overview
                     15.2.5. Strategic Overview
           15.3. Merck & Co
                     15.3.1. Company Overview
                     15.3.2. Product Portfolio
                     15.3.3. SWOT Analysis
                     15.3.4. Financial Overview
                     15.3.5. Strategic Overview
           15.4. Novartis International AG
                     15.4.1. Company Overview
                     15.4.2. Product Portfolio
                     15.4.3. SWOT Analysis
                     15.4.4. Financial Overview
                     15.4.5. Strategic Overview
           15.5 Johnson & Johnson
                     15.5.1. Company Overview
                     15.5.2. Product Portfolio
                     15.5.3. SWOT Analysis
                     15.5.4. Financial Overview
                     15.5.5. Strategic Overview
           15.6  Sanofi
                     15.6.1. Company Overview
                     15.6.2. Product Portfolio
                     15.6.3. SWOT Analysis
                     15.6.4. Financial Overview
                     15.6.5. Strategic Overview
           15.7. GlaxoSmithKline Plc
                     15.7.1. Company Overview
                     15.7.2. Product Portfolio
                     15.7.3. SWOT Analysis
                     15.7.4. Financial Overview
                     15.7.5. Strategic Overview
           15.8. Amgen Inc.
                     15.8.1. Company Overview
                     15.8.2. Product Portfolio
                     15.8.3. SWOT Analysis
                     15.8.4. Financial Overview
                     15.8.5. Strategic Overview
           15.9. AbbVie Inc.
                     15.9.1. Company Overview
                     15.9.2. Product Portfolio
                     15.9.3. SWOT Analysis
                     15.9.4. Financial Overview
                     15.9.5. Strategic Overview
           15.10. Boehringer Ingelheim
                     15.10.1. Company Overview
                     15.10.2. Product Portfolio
                     15.10.3. SWOT Analysis
                     15.10.4. Financial Overview
                     15.10.5. Strategic Overview
           15.11. AstraZeneca
                     15.11.1. Company Overview
                     15.11.2. Product Portfolio
                     15.11.3. SWOT Analysis
                     15.11.4. Financial Overview
                     15.11.5. Strategic Overview
           15.12. Immatics Biotechnologies
                     15.12.1. Company Overview
                     15.12.2. Product Portfolio
                     15.12.3. SWOT Analysis
                     15.12.4. Financial Overview
                     15.12.5. Strategic Overview
           15.13. Biontech SE
                     15.13.1. Company Overview
                     15.13.2. Product Portfolio
                     15.13.3. SWOT Analysis
                     15.13.4. Financial Overview
                     15.13.5. Strategic Overview
           15.14. Genmab
                     15.14.1. Company Overview
                     15.14.2. Product Portfolio
                     15.14.3. SWOT Analysis
                     15.14.4. Financial Overview
                     15.14.5. Strategic Overview
           15.15. Gilead Sciences
                     15.15.1. Company Overview
                     15.15.2. Product Portfolio
                     15.15.3. SWOT Analysis
                     15.15.4. Financial Overview
                     15.15.5. Strategic Overview
           15.16. NBE Therapeutics
                     15.16.1. Company Overview
                     15.16.2. Product Portfolio
                     15.16.3. SWOT Analysis
                     15.16.4. Financial Overview
                     15.16.5. Strategic Overview
           15.17. Teva Pharmaceuticals
                     15.17.1. Company Overview
                     15.17.2. Product Portfolio
                     15.17.3. SWOT Analysis
                     15.17.4. Financial Overview
                     15.17.5. Strategic Overview
           15.18. Bayer
                     15.18.1. Company Overview
                     15.18.2. Product Portfolio
                     15.18.3. SWOT Analysis
                     15.18.4. Financial Overview
                     15.18.5. Strategic Overview
           15.19. Bristol-Myers Squibb.
                    15.19.1. Company Overview
                    15.19.2. Product Portfolio
                    15.19.3. SWOT Analysis
                    15.19.4. Financial Overview
                    15.19.5. Strategic Overview
           15.20. Eli Lilly And Company
                    15.20.1. Company Overview
                    15.20.2. Product Portfolio
                    15.20.3. SWOT Analysis
                    15.20.4. Financial Overview
                    15.20.5. Strategic Overview
           15.21. Incyte Corporation
                    15.21.1. Company Overview
                    15.21.2. Product Portfolio
                    15.21.3. SWOT Analysis
                    15.21.4. Financial Overview
                    15.21.5. Strategic Overview
16. FutureWise SME Key Takeaway Points for Client

Tables

Figures